| Bioactivity | Arazine (N-Acetyl-S-farnesyl-L-cysteine) is a cell-permeable modulator of G protein and G-protein coupled receptor signaling. Arazine can be a a substrate for isoprenylcysteine methyltransferase by competing with prenylated G protein or its receptors site[1]. |
| Invitro | Arazine (2 hours) inhibits ATPγS induced CXCL1, CXCL8 and CCL2 production as a dose-dependent manner in HMEC-1 cell[1].Arazine (10–100 μM;8 hours) significantly affects the HMEC-1 cell viability as measured by trypan blue exclusion in HMEC-1 cell[1]. |
| In Vivo | Arazine (AFC) (2,000 μg/20 μl; applied on ear) produces a dose-dependent inhibition of the TPA-induced edema, with the maximal reduction of edema approaching 73%, with a 50% effective dose (ED50) of 55±12 μg/20 μl[1]. Animal Model: |
| Name | Arazine |
| CAS | 135304-07-3 |
| Formula | C20H33NO3S |
| Molar Mass | 367.55 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Solution, -20°C, 2 years |
| Reference | [1]. Gordon JS, et al. Topical N-acetyl-S-farnesyl-L-cysteine inhibits mouse skin inflammation, and unlike dexamethasone, its effects are restricted to the application site.J Invest Dermatol. 2008 Mar;128(3):643-54. Epub 2007 Sep 20. [2]. Adhami K, et al. N-acetyl-S-farnesyl-l-cysteine suppresses chemokine production by human dermal microvascular endothelial cells.Exp Dermatol. 2012 Sep;21(9):700-5. |